FindTrial
Sign In

Evaluation of the Efficacy of Oral Probiotics as an Adjuvant Therapy for Vaginal Infections

Evaluation of the Efficacy of Oral Probiotics as an Adjuvant Therapy for Vaginal Infections

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112201
Enrollment
Unknown
Registered
2025-11-11
Start date
2025-12-05
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginitis

Interventions

Group L1: Lactobacillus crispatus CCFM1298 powder:Take the oral powder of Lactobacillus crispatus CCFM1298 twice a day, once in the morning and once in the evening, for a continuous period of 28 days.
Group L2: Lactobacillus johnsonii CCFM1314 powder:Take the oral powder of Lactobacillus johnsonii CCFM1314 twice a day, once in the morning and once in the evening, for a continuous period of 28 days
Group L3: Lactobacillus gasseri CCFM1430 powder:Take the oral powder of Lactobacillus gasseri CCFM1430 twice a day, once in the morning and once in the evening, for a continuous period of 28 days.
Group L4: Limosilactobacillus reuteri CCFM1432 powder:Take the oral powder of Limosilactobacillus reuteri CCFM1432 twice a day, once in the morning and once in the evening, for a continuous period of
Group L5: Lactobacillus gasseri CCFM1336 powder:Take the oral powder of Lactobacillus gasseri CCFM1336 twice a day, once in the morning and once in the evening, for a continuous period of 28 days.
Group L6: Lactobacillus crispatus CCFM1339 powder:Take the oral powder of Lactobacillus crispatus CCFM1339 twice a day, once in the morning and once in the evening, for a continuous period of 28 days.
Control Group (Group C): Other excipient ingredients without probiotics:Take the oral excipient twice a day, once in the morning and once in the evening, for a continuous period of 28 days.

Sponsors

Yixing Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of vaginitis in western medicine; 2. Age >= 18 and <= 65; 3. It is the resident population where the hospital is located; 4. No malignant tumor of reproductive tract, no history of hysterectomy and pelvic radiotherapy; 5. The patient volunteered to participate in the trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with sexually transmitted diseases. 2. Patients with other severe gynecological diseases, such as gynecological malignancies and pelvic inflammatory disease. 3. Individuals who have received any oral or topical medication for this condition within one week prior to enrollment. 4. Pregnant and breastfeeding women or those planning to become pregnant in the near future. 5. Individuals with systemic immune diseases and neuropsychiatric disorders. 6. Individuals with a history of estrogen or estrogen-like drug use within three months prior to study enrollment.

Design outcomes

Primary

MeasureTime frame
Routine Vaginal Secretions Test;Vaginal Secretion Metagenome;—

Secondary

MeasureTime frame
IL-1ß;TNF-a;IL-8;sIgA;IgG;HBD;E-cadherin;—

Countries

China

Contacts

Public ContactCao Yan;Wang Zhuxiu

Yixing Traditional Chinese Medicine Hospital

272260877@qq.com+86 139 6157 8200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026